A major global trial shows that starting evolocumab early, before a first heart attack or stroke, lowers cardiovascular risk and strengthens the case for aggressive LDL cholesterol reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback